Evidence map›Paper›PMID 29315235›Full record

ArticleBioengineering (Basel, Switzerland)2018

Response of Fibroblasts MRC-5 to Flufenamic Acid-Grafted MCM-41 Nanoparticles.

Giovanna Gomes Lara, Marcelo Fernandes Cipreste, Gracielle Ferreira Andrade, Wellington Marcos da Silva, Edésia Martins Barros de Sousa

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giovanna Gomes LaraCentro de Desenvolvimento da Tecnologia Nuclear-CDTN-Avenida Presidente Antônio Carlos, 6.627-Campus UFMG, Belo Horizonte CEP 31270-901, Minas Gerais, Brazil. gilara2009@gmail.com.
Marcelo Fernandes CipresteCentro de Desenvolvimento da Tecnologia Nuclear-CDTN-Avenida Presidente Antônio Carlos, 6.627-Campus UFMG, Belo Horizonte CEP 31270-901, Minas Gerais, Brazil. mcipreste@gmail.com.ORCID 0000-0002-8969-3063
Gracielle Ferreira AndradeCentro de Desenvolvimento da Tecnologia Nuclear-CDTN-Avenida Presidente Antônio Carlos, 6.627-Campus UFMG, Belo Horizonte CEP 31270-901, Minas Gerais, Brazil. graciellefandrade@yahoo.com.
Wellington Marcos da SilvaCentro de Desenvolvimento da Tecnologia Nuclear-CDTN-Avenida Presidente Antônio Carlos, 6.627-Campus UFMG, Belo Horizonte CEP 31270-901, Minas Gerais, Brazil. wellingtonmarcos@yahoo.com.br.
Edésia Martins Barros de SousaCentro de Desenvolvimento da Tecnologia Nuclear-CDTN-Avenida Presidente Antônio Carlos, 6.627-Campus UFMG, Belo Horizonte CEP 31270-901, Minas Gerais, Brazil. sousaem@cdtn.br.ORCID 0000-0002-6317-4054

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, flufenamic acid (FFA) was discovered among fenamates as a free radical scavenger and gap junction blocker; however, its effects have only been studied in cancer cells. Normal cells in the surroundings of a tumor also respond to radiation, although they are not hit by it directly. This phenomenon is known as the bystander effect, where response molecules pass from tumor cells to normal ones, through communication channels called gap junctions. The use of the enhanced permeability and retention effect, through which drug-loaded nanoparticles smaller than 200 nm may accumulate around a tumor, can prevent the local side effect upon controlled release of the drug. The present work, aimed at functionalizing MCM-41 (Mobil Composition of Matter No. 41) silica nanoparticles with FFA and determining its biocompatibility with human fibroblasts MRC-5 (Medical Research Council cell strain 5). MCM-41, was synthesized and characterized structurally and chemically, with multiple techniques. The biocompatibility assay was performed by Live/Dead technique, with calcein and propidium-iodide. MRC-5 cells were treated with FFA-grafted MCM-41 for 48 h, and 98% of cells remained viable, without signs of necrosis or morphological changes. The results show the feasibility of MCM-41 functionalization with FFA, and its potential protection of normal cells, in comparison to the role of FFA in cancerous ones.

Indexed as

biocompatibilityflufenamic acidfunctionalizationMCM-41MRC-5 cells

Identifiers

PMID29315235
PMCPMC5874870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.